ECO Animal Health Group plc (AIM:EAH)

Market Cap	49.80M
Revenue (ttm)	79.60M
Net Income (ttm)	1.69M
Shares Out	67.76M
EPS (ttm)	0.02
PE Ratio	30.25
Forward PE	26.51
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,107
Average Volume	44,458
Open	73.77
Previous Close	73.50
Day's Range	73.36 - 73.95
52-Week Range	50.00 - 120.70
Beta	-0.01
RSI	55.59
Earnings Date	Aug 29, 2025

About ECO Animal Health Group

ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, lices, and mange in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1972
• Employees: 224
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: EAH

Financial Performance

In 2024, ECO Animal Health Group's revenue was 79.60 million, a decrease of -10.99% compared to the previous year's 89.42 million. Earnings were 1.69 million, an increase of 60.88%.